MEA Stroke Market - Industry Trends and Forecast to 2033

Description

List of Tables

Middle East and Africa stroke market is projected to register a CAGR of 5.3% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (Saudi Arabia, UAE, South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East And Africa) - Industry trends and forecast to 2030.

Overview of Middle East and Africa Stroke Market Dynamics

Drivers
Rising incidences of stroke
Increasing number of patients with hypertension and coronary heart diseases
Restraints
High cost associated with treatment of stroke
Side-effects associated with medication
Opportunities
Expansion of telemedicine and remote monitoring
Innovative therapies in pipeline for stroke treatment

Market Players

Some of the major market players operating in the Middle East and Africa stroke market are:

Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH.
F. Hoffmann-La Roche Ltd
DAIICHI SANKYO COMPANY, LIMITED.
Sanofi
Johnson & Johnson Services, Inc.
Bayer AG
Sandoz AG
Pfizer Inc.
Medtronic
Abbott
Viatris Inc.
AstraZeneca
GLENMARK PHARMACEUTICALS LTD

1 INTRODUCTION 28

1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA STROKE MARKET 28
1.4 LIMITATIONS 30
1.5 MARKETS COVERED 30

2 MARKET SEGMENTATION 35

2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 TYPE LIFELINE CURVE 42
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.9 DBMR MARKET POSITION GRID 44
2.10 MARKET APPLICATION COVERAGE GRID 45
2.11 VENDOR SHARE ANALYSIS 46
2.12 SECONDARY SOURCES 47
2.13 ASSUMPTIONS 47

3 EXECUTIVE SUMMARY 48

4 PREMIUM INSIGHTS 51

4.1 PESTEL'S MODEL 52
4.2 PORTER'S 5 FORCES 53

5 EPIDEMIOLOGY 54

6 MIDDLE EAST AND AFRICA STROKE MARKET, REGULATORY FRAMEWORK 55

6.1 REGULATION IN U.S 55
6.2 REGULATION IN EUROPE 56
6.3 REGULATION IN CHINA 57
6.4 REGULATION IN JAPAN 58
6.5 REGULATION IN SOUTH AFRICA 59

7 MARKET OVERVIEW 60

7.1 DRIVERS 62
- 7.1.1 RISING INCIDENCES OF STROKE 62
- 7.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 63
- 7.1.3 INCREASING DIABETIC AND OBESE POPULATION 64
- 7.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR STROKE TREATMENT 65
7.2 RESTRAINTS 66
- 7.2.1 HIGH COST ASSOCIATED WITH TREATMENT OF STROKE 66
- 7.2.2 SIDE-EFFECTS ASSOCIATED WITH MEDICATION 67
7.3 OPPORTUNITIES 68
- 7.3.1 EXPANSION OF TELEMEDICINE AND REMOTE MONITORING 68
- 7.3.2 INNOVATIVE THERAPIES IN PIPELINE FOR STROKE TREATMENT 68
7.4 CHALLENGES 69
- 7.4.1 INACCURATE DIAGNOSIS OF STROKES S 69
- 7.4.2 COMPLICATIONS IN MANAGING STROKE IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS 70

8 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE 71

8.1 OVERVIEW 72
8.2 ISCHEMIC STROKE 75
- 8.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 76
- 8.2.2 EMBOLIC (CEREBRAL EMBOLISM) 76
8.3 HEMORRHAGIC STROKE 77
- 8.3.1 SUBARACHNOID HEMORRHAGE 78
- 8.3.2 INTRACEREBRAL HEMORRHAGE 78
8.4 TRANSIENT ISCHEMIC ATTACK (TIA) 78

9 MIDDLE EAST AND AFRICA STROKE MARKET, BY TREATMENT 79

9.1 OVERVIEW 80
9.2 MEDICATION 83
- 9.2.1 BY CLASS 84
  - 9.2.1.1 BLOOD PRESSURE MEDICINES 85
    - 9.2.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 86
    - 9.2.1.1.1.1 RAMIPRIL 86
    - 9.2.1.1.1.2 LISINOPRIL 86
    - 9.2.1.1.1.3 ENALAPRIL 86
    - 9.2.1.1.1.4 PERINDOPRIL 86
    - 9.2.1.1.1.5 OTHER 87

9.2.1.1.2 DIURETICS 87
9.2.1.1.2.1 INDAPAMIDE 87
9.2.1.1.2.2 BENDROFLUMETHIAZIDE 87
9.2.1.1.2.3 SPIRONOLACTONE 87
9.2.1.1.2.4 AMILORIDE 88
9.2.1.1.2.5 OTHER 88
9.2.1.1.3 CALCIUM CHANNEL BLOCKERS 88
9.2.1.1.3.1 AMLODIPINE 88
9.2.1.1.3.2 NIFEDIPINE 88
9.2.1.1.3.3 VERAPAMIL 89
9.2.1.1.3.4 NICARDIPINE 89
9.2.1.1.3.5 FELODIPINE 89
9.2.1.1.3.6 NIMODIPINE 89
9.2.1.1.3.7 OTHER 89
9.2.1.1.4 BETA BLOCKERS 90
9.2.1.1.4.1 ATENOLOL 90
9.2.1.1.4.2 BISOPROLOL 90
9.2.1.1.4.3 LABETOLOL 90
9.2.1.1.4.4 OTHER 90
9.2.1.1.5 ALPHA BLOCKERS 91
9.2.1.1.5.1 DOXAZOSIN 91
9.2.1.1.5.2 OTHER 91
9.2.1.1.6 OTHERS 91

9.2.1.1 ANTIPLATELET DRUGS 92
- 9.2.1.1.1 ASPIRIN 92
- 9.2.1.1.2 CLOPIDOGREL 92
- 9.2.1.1.3 DIPYRIDAMOLE 92
- 9.2.1.1.4 TICLOPIDINE 92
- 9.2.1.1.5 OTHERS 92
9.2.1.2 ANTICOAGULANTS 93
- 9.2.1.2.1 WARFARIN 93
- 9.2.1.2.2 APIXABAN 93
- 9.2.1.2.3 DABIGATRAN 93
- 9.2.1.2.4 HEPARIN 93
- 9.2.1.2.5 RIVAROXABAN 94
- 9.2.1.2.6 OTHERS 94
9.2.1.3 TISSUE PLASMINOGEN ACTIVATOR (TPA) 94
- 9.2.1.3.1 ALTEPLASE 94
- 9.2.1.3.2 TENECTEPLASE 94
- 9.2.1.3.3 RETEPLASE 94
- 9.2.1.3.4 ANISTREPLASE 95
- 9.2.1.3.5 OTHERS 95
9.2.1.4 STATINS 95
- 9.2.1.4.1 ATORVASTATIN 95
- 9.2.1.4.2 SIMVASTATIN 95
- 9.2.1.4.3 LOVASTATIN 95
- 9.2.1.4.4 ROSUVASTATIN 96
- 9.2.1.4.5 FLUVASTATIN 96
- 9.2.1.4.6 PRAVASTATIN 96
- 9.2.1.4.7 PITAVASTATIN 96
- 9.2.1.4.8 OTHERS 96
9.2.1.5 VITAMIN K 96
9.2.1.6 SUPPORTIVE MEDICATION 97
- 9.2.1.6.1 NUTRITIONAL SUPPLEMENTS 97
- 9.2.1.6.2 ANTIPYRETICS 97
- 9.2.1.6.3 OTHERS 97

9.2.2 BY DRUG TYPE 98
- 9.2.2.1 GENERICS 98
- 9.2.2.2 BRANDED 99
  - 9.2.2.2.1 ELIQUIS 99
  - 9.2.2.2.2 PRADAXA 99
  - 9.2.2.2.3 ACTIVASE 99
  - 9.2.2.2.4 ASPIRIN 100
  - 9.2.2.2.5 PLAVIX 100
  - 9.2.2.2.6 AGGRENOX 100
  - 9.2.2.2.7 OTHERS 100
9.2.3 BY ROUTE OF ADMINISTRATION 101
- 9.2.3.1 ORAL 101
  - 9.2.3.1.1 TABLET 102
  - 9.2.3.1.2 CAPSULES 102
  - 9.2.3.1.3 Others 102
- 9.2.3.2 PARENTERAL 103
  - 9.2.3.2.1 INTRAVENOUS 103
  - 9.2.3.2.2 SUBCUTANEOUS 103
- 9.2.3.3 OTHERS 103
9.2.4 BY MODE OF PURCHASE 104
- 9.2.4.1 PRESCRIPTION 104
- 9.2.4.2 OVER THE COUNTER (OTC) 104
9.2.5 BY THERPAY TYPE 105
- 9.2.5.1 COMBINATION THERAPY 105
- 9.2.5.2 MONOTHERAPY 105

9.3 SURGERY 106
- 9.3.1 EMBOLIC COILS 107
- 9.3.2 ASPIRATION CATHETERS 107
- 9.3.3 STENT RETRIEVER 107
- 9.3.4 SURGICAL CLIPPING 107
- 9.3.5 OTHERS 107
9.4 OTHER THERAPY 108
- 9.4.1 PHYSICAL THERAPY 108
- 9.4.2 OCCUPATIONAL THERAPY 108
- 9.4.3 SPEECH THERAPY 109
- 9.4.4 OTHERS 109

10 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS 110

10.1 OVERVIEW 111
10.2 IMAGING TEST 114
- 10.2.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 114
- 10.2.2 MAGNETIC RESONANCE IMAGING (MRI) 115
- 10.2.3 CAROTID ULTRASOUND 115
- 10.2.4 CEREBRAL ANGIOGRAM 115
10.3 BLOOD TEST 116
10.4 ECHOCARDIOGRAM 116
10.5 LUMBAR PUNCTURE 117
10.6 OTHERS 117

11 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER 118

11.1 OVERVIEW 119
11.2 FEMALE 122
11.3 MALE 123

12 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER 124

12.1 OVERVIEW 125
12.2 HOSPITALS & CLINICS 128
12.3 SPECIALTY CLINICS 129
12.4 AMBULATORY SURGICAL CENTER 129
12.5 HOMECARE 130
12.6 LABORATORIES 130
12.7 OTHERS 131

13 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL 132

13.1 OVERVIEW 133
13.2 DIRECT 136
13.3 RETAIL 136
13.4 ONLINE 137

14 MIDDLE EAST AND AFRICA STROKE MARKET, BY REGION 138

14.1 MIDDLE EAST AND AFRICA 140
- 14.1.1 SAUDI ARABIA 150
- 14.1.2 U.A.E. 158
- 14.1.3 SOUTH AFRICA 166
- 14.1.4 EGYPT 174
- 14.1.5 QATAR 182
- 14.1.6 KUWAIT 190
- 14.1.7 OMAN 198
- 14.1.8 BAHRAIN 206
- 14.1.9 REST OF MIDDLE EAST AND AFRICA 214

15 MIDDLE EAST AND AFRICA STROKE MARKET, COMPANY LANDSCAPE 215

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 215

16 SWOT ANALYSIS 216

17 COMPANY PROFILES 217

17.1 BRISTOL-MYERS SQUIBB COMPANY 217
- 17.1.1 COMPANY SNAPSHOT 217
- 17.1.2 REVENUE ANALYSIS 217
- 17.1.3 COMPANY SHARE ANALYSIS 218
- 17.1.4 PRODUCT PORTFOLIO 218
- 17.1.5 RECENT DEVELOPMENT 219
17.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 220
- 17.2.1 COMPANY SNAPSHOT 220
- 17.2.2 PRODUCT PORTFOLIO 220
- 17.2.3 COMPANY SHARE ANALYSIS 221
- 17.2.4 RECENT DEVELOPMENT 221
17.3 F. HOFFMANN-LA ROCHE LTD 222
- 17.3.1 COMPANY SNAPSHOT 222
- 17.3.2 REVENUE ANALYSIS 222
- 17.3.3 COMPANY SHARE ANALYSIS 223
- 17.3.4 PRODUCT PORTFOLIO 223

17.3.5 RECENT DEVELOPMENT 223

17.4 DAIICHI SANKYO COMPANY, LIMITED 224
- 17.4.1 COMPANY SNAPSHOT 224
- 17.4.2 REVENUE ANALYSIS 224
- 17.4.3 COMPANY SHARE ANALYSIS 225
- 17.4.4 PRODUCT PORTFOLIO 225
- 17.4.5 RECENT DEVELOPMENT 226
17.5 SANOFI 227
- 17.5.1 COMPANY SNAPSHOT 227
- 17.5.2 REVENUE ANALYSIS 227
- 17.5.3 COMPANY SHARE ANALYSIS 228
- 17.5.4 PRODUCT PORTFOLIO 228
- 17.5.5 RECENT DEVELOPMENT 228
17.6 ABBOTT 230
- 17.6.1 COMPANY SNAPSHOT 230
- 17.6.2 REVENUE ANALYSIS 230
- 17.6.3 PRODUCT PORTFOLIO 231
- 17.6.4 RECENT DEVELOPMENT 232
17.7 AMNEAL PHARMACEUTICALS LLC 233
- 17.7.1 COMPANY SNAPSHOT 233
- 17.7.2 REVENUE ANALYSIS 233
- 17.7.3 PRODUCT PORTFOLIO 234
- 17.7.4 RECENT DEVELOPMENT 234
17.8 ASTRAZENECA 235
- 17.8.1 COMPANY SNAPSHOT 235
- 17.8.2 REVENUE ANALYSIS 236
- 17.8.3 PRODUCT PORTFOLIO 236
- 17.8.4 RECENT DEVELOPMENT 236
17.9 BAYER AG 237
- 17.9.1 COMPANY SNAPSHOT 237
- 17.9.2 REVENUE ANALYSIS 238
- 17.9.3 PRODUCT PORTFOLIO 238
- 17.9.4 RECENT DEVELOPMENT 239
17.10 FRESENIUS SE & CO. KGAA 240
- 17.10.1 COMPANY SNAPSHOT 240
- 17.10.2 REVENUE ANALYSIS 240
- 17.10.3 PRODUCT PORTFOLIO 241
- 17.10.4 RECENT DEVELOPMENT 241
17.11 GLENMARK PHARMACEUTICALS LTD. 242
- 17.11.1 COMPANY SNAPSHOT 242
- 17.11.2 REVENUE ANALYSIS 243
- 17.11.3 PRODUCT PORTFOLIO 243
- 17.11.4 RECENT DEVELOPMENT 243
17.12 JOHNSON & JOHNSON SERVICES, INC. 245
- 17.12.1 COMPANY SNAPSHOT 245
- 17.12.2 REVENUE ANALYSIS 245
- 17.12.3 PRODUCT PORTFOLIO 246
- 17.12.4 RECENT DEVELOPMENT 246
17.13 LUPIN 247
- 17.13.1 COMPANY SNAPSHOT 247
- 17.13.2 REVENUE ANALYSIS 247
- 17.13.3 PRODUCT PORTFOLIO 248
- 17.13.4 RECENT DEVELOPMENT 249
17.14 MEDTRONIC 250
- 17.14.1 COMPANY SNAPSHOT 250
- 17.14.2 REVENUE ANALYSIS 250
- 17.14.3 PRODUCT PORTFOLIO 251
- 17.14.4 RECENT DEVELOPMENT 251
17.15 OXFORD LABORATORIES PVT. LTD. 252
- 17.15.1 COMPANY SNAPSHOT 252
- 17.15.2 PRODUCT PORTFOLIO 252
- 17.15.3 RECENT DEVELOPMENT 252
17.16 PENUMBRA, INC. 253
- 17.16.1 COMPANY SNAPSHOT 253
- 17.16.2 REVENUE ANALYSIS 253
- 17.16.3 PRODUCT PORTFOLIO 254
- 17.16.4 RECENT DEVELOPMENT 254
17.17 PFIZER INC. 255
- 17.17.1 COMPANY SNAPSHOT 255
- 17.17.2 REVENUE ANALYSIS 255
- 17.17.3 PRODUCT PORTFOLIO 256
- 17.17.4 RECENT DEVELOPMENT 256
17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 257
- 17.18.1 COMPANY SNAPSHOT 257
- 17.18.2 REVENUE ANALYSIS 257
- 17.18.3 PRODUCT PORTFOLIO 258
- 17.18.4 RECENT DEVELOPMENT 258
17.19 TEVA PHARMACEUTICALS USA, INC. 259
- 17.19.1 COMPANY SNAPSHOT 259
- 17.19.2 REVENUE ANALYSIS 259
- 17.19.3 PRODUCT PORTFOLIO 260
- 17.19.4 RECENT DEVELOPMENT 260
17.20 VIATRIS INC. 261
- 17.20.1 COMPANY SNAPSHOT 261
- 17.20.2 REVENUE ANALYSIS 261
- 17.20.3 PRODUCT PORTFOLIO 262
- 17.20.4 RECENT DEVELOPMENT 262

18 QUESTIONNAIRE 263

19 RELATED REPORTS 267

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION 35
FIGURE 2 MIDDLE EAST AND AFRICA STROKE MARKET: DATA TRIANGULATION 38
FIGURE 3 MIDDLE EAST AND AFRICA STROKE MARKET: DROC ANALYSIS 39
FIGURE 4 MIDDLE EAST AND AFRICA STROKE MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 40
FIGURE 5 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY RESEARCH ANALYSIS 40
FIGURE 6 MIDDLE EAST AND AFRICA STROKE MARKET: INTERVIEW DEMOGRAPHICS 43
FIGURE 7 MIDDLE EAST AND AFRICA STROKE MARKET: DBMR MARKET POSITION GRID 44
FIGURE 8 MIDDLE EAST AND AFRICA STROKE MARKET: MARKET APPLICATION COVERAGE GRID 45
FIGURE 9 MIDDLE EAST AND AFRICA STROKE MARKET: VENDOR SHARE ANALYSIS 46
FIGURE 10 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION 50
FIGURE 11 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 51
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA STROKE MARKET IN THE FORECAST PERIOD OF 2023 & 2030 51
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA STROKE MARKET 61
FIGURE 14 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2022 72
FIGURE 15 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 73
FIGURE 16 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, CAGR (2023-2030) 73
FIGURE 17 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, LIFELINE CURVE 74
FIGURE 18 MIDDLE EAST AND AFRICA STROKE MARKET: BY TREATMENT, 2022 80
FIGURE 19 MIDDLE EAST AND AFRICA STROKE MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 81
FIGURE 20 MIDDLE EAST AND AFRICA STROKE MARKET: BY TREATMENT, CAGR (2023-2030) 81
FIGURE 21 MIDDLE EAST AND AFRICA STROKE MARKET: BY TREATMENT, LIFELINE CURVE 82
FIGURE 22 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS, 2022 111
FIGURE 23 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS, 2023-2030 (USD THOUSAND) 112
FIGURE 24 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS, CAGR (2023-2030) 112
FIGURE 25 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS, LIFELINE CURVE 113
FIGURE 26 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2022 119
FIGURE 27 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 120
FIGURE 28 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, CAGR (2023-2030) 120
FIGURE 29 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, LIFELINE CURVE 121
FIGURE 30 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2022 125
FIGURE 31 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2023-2030 (USD THOUSAND) 126
FIGURE 32 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, CAGR (2023-2030) 126
FIGURE 33 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, LIFELINE CURVE 127
FIGURE 34 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2022 133
FIGURE 35 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 134
FIGURE 36 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 134
FIGURE 37 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 135
FIGURE 38 MIDDLE EAST AND AFRICA STROKE MARKET: SNAPSHOT (2022) 139
FIGURE 39 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY SHARE 2022 (%) 215